Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy (NCT05337631)
🩺 Plain-English Summary (8th-Grade Level)
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing; however, the evidence regarding the ideal treatment for this often vulnerable and frail patient cohort is limited. Although the benefit of concomitant chemotherapy has been reported to decrease in elderly HNSCC patients based on the MACH-NC meta-analysis, it remains unknown whether state-of-the art radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), modern supportive treatments and alternative chemotherapy fractionation (e.g., cisplatin weekly) may have altered this observation. The objective of this retrospective multinational multicenter study is to determine the oncological outcomes of elderly patients (≥65 years) with locally advanced HNSCCs undergoing definitive (chemo-)radiation and to investigate the influence of concomitant chemotherapy on overall survival and progression-free survival after adjusting for potential confounder variables such as age, performance status and comorbidity burden.
Who can join: Review the eligibility criteria below.
Location: Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine — Baltimore, Maryland
Age range: 65 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine — Baltimore, Maryland
- Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai — New York, New York
- Department of Radiation Oncology, Case Western Reserve University — Cleveland, Ohio
- Division of Radiation Oncology, The Ohio State University Wexner — Columbus, Ohio
- Radiation Oncology Department, German Oncology Center — Limassol,
- Brno University Hospital — Brno,
- Department of Radiooncology and Radiotherapy, Charité-Universitätsmedizin Berlin — Berlin,
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg — Erlangen,
- Department of Radiotherapy and Oncology, Goethe-University Frankfurt am Main — Frankfurt,
- University of Giessen — Giessen,
- Martin-Luther-Universität Halle-Wittenberg — Halle,
- Jena University Hospital — Jena,
- Department of Radiation Oncology, University Hospital Schleswig-Holstein — Kiel,
- Department of Radiation Oncology, University Medical Center Leipzig — Leipzig,
- Department of Radiation Oncology, University Medical Center Mainz — Mainz,
- Department of Radiation Oncology, University Hospital, LMU Munich — Munich,
- Department of Radiation Oncology, University Hospital Würzburg — Würzburg,
- Department of Radiation Oncology, University Hospital Zurich (USZ), University of Zurich (UZH) — Zurich,
📞 Contact the Study Coordinator
Phone: 004976127095200
Email: alexander.ruehle@uniklinik-freiburg.de
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HNSCC
- Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors — Portland, Oregon
- Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC — Cincinnati, Ohio
- Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) — Nashville, Tennessee
- Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC — Orange, California
- A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors — Denver, Colorado
- Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer — Nashville, Tennessee
Explore by condition: All HNSCC clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.